|
- Pfizer Inc. - Investor Relations
We're elevating our breakthroughs in a bold new way on Pfizer com Check out our new visualized product pipeline, where you'll be able to take a deep dive into our working innovations and see where each product is in development!
- Investor Relations - Shareholder Services - Pfizer Inc.
Our recent proxy statements for shareholder meetings, which are also filed with the SEC and are available at http: www sec gov and http: www pfizer com, also contain important information
- Pfizer Inc. - Investor Relations - Events Presentations - Pfizer Pflash
Forward-Looking Statements of Pfizer Inc This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical
- Pfizer Inc. - Investor Relations - Stock Info - Dividend Split History
A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form
- Pfizer Inc. - Why Invest
Pfizer Inc is a research-based, global biopharmaceutical company We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of medicines and vaccines
- Pfizer Inc. - Investor Relations - Corporate Governance - Board . . .
Under the terms of its Charter, the Compensation Committee is directly responsible for establishing annual and long-term performance goals, and objectives for our elected officers
- Home - Pfizer Investor Insights
Pfizer delivered solid first-quarter 2025 financial results, while continuing to execute with focus and discipline against its 2025 strategic priorities The company made progress strengthening its research and development (R D) organization, executing on cost savings initiatives, and deploying capital to support long-term growth Read more
- Resources - Pfizer Investor Insights
Obtain detailed information about our financial and operational performance Our continued focus is to deliver value to our shareholders Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders
|
|
|